$TCRT
Alaunos Therapeutics, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515177165 Filed on May 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $270.0K $270.0K $200.0K
YoY Change 35.0% 35.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.070M $4.250M $3.440M
YoY Change 133.33% 23.55% -26.34%
% of Gross Profit
Research & Development $7.424M $74.25M $6.542M
YoY Change -11.05% 1034.96% -65.77%
% of Gross Profit
Depreciation & Amortization $120.0K $120.0K $120.0K
YoY Change 20.0% 0.0% -40.0%
% of Gross Profit
Operating Expenses $7.424M $74.25M $6.542M
YoY Change -11.05% 1034.96% -65.77%
Operating Profit -$14.23M -$78.23M -$9.784M
YoY Change 27.27% 699.54% -58.51%
Interest Expense $0.00 $0.00 $80.00K
YoY Change -100.0% -100.0% -99.26%
% of Operating Profit
Other Income/Expense, Net $14.00K -$4.000K -$9.000K
YoY Change 1300.0% -55.56% 125.0%
Pretax Income -$14.21M -$78.23M -$9.710M
YoY Change 154.66% 705.66% -24.14%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.21M -$78.23M -$9.711M
YoY Change 154.86% 705.59% -24.13%
Net Earnings / Revenue -5263.33% -28974.44% -4855.5%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.11 -$0.69 -$0.10
COMMON SHARES
Basic Shares Outstanding 128.2M shares 114.7M shares 100.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $118.6M $129.7M $60.40M
YoY Change 123.77% 114.74% 8.44%
Cash & Equivalents $118.6M $129.7M $60.39M
Short-Term Investments
Other Short-Term Assets $4.400M $900.0K $1.600M
YoY Change 340.0% -43.75% -66.67%
Inventory
Prepaid Expenses
Receivables $100.0K $100.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $123.1M $130.6M $62.00M
YoY Change 127.82% 110.65% 2.38%
LONG-TERM ASSETS
Property, Plant & Equipment $321.0K $426.0K $679.0K
YoY Change -53.0% -37.26% -64.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $509.0K $491.0K $517.0K
YoY Change -0.78% -5.03% -30.42%
Total Long-Term Assets $958.0K $1.045M $1.324M
YoY Change -27.64% -21.07% -52.46%
TOTAL ASSETS
Total Short-Term Assets $123.1M $130.6M $62.00M
Total Long-Term Assets $958.0K $1.045M $1.324M
Total Assets $124.0M $131.6M $63.33M
YoY Change 124.11% 107.89% -0.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.143M $779.0K $578.0K
YoY Change 603.13% 34.78% -41.2%
Accrued Expenses $8.752M $8.220M $5.752M
YoY Change 12.59% 42.91% -68.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.11M $10.49M $7.354M
YoY Change 21.52% 42.67% -63.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.00K $600.0K $20.00K
YoY Change -15.0% 2900.0% -99.08%
Total Long-Term Liabilities $17.00K $600.0K $20.00K
YoY Change -15.0% 2900.0% -99.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.11M $10.49M $7.354M
Total Long-Term Liabilities $17.00K $600.0K $20.00K
Total Liabilities $13.60M $11.05M $21.59M
YoY Change -22.88% -48.85% -15.17%
SHAREHOLDERS EQUITY
Retained Earnings -$465.1M -$450.8M
YoY Change 30.59%
Common Stock $575.5M $571.4M $388.7M
YoY Change 47.45% 47.03% 18.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $110.4M $120.6M $41.73M
YoY Change
Total Liabilities & Shareholders Equity $124.0M $131.6M $63.33M
YoY Change 124.11% 107.89% -0.03%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$14.21M -$78.23M -$9.711M
YoY Change 154.86% 705.59% -24.13%
Depreciation, Depletion And Amortization $120.0K $120.0K $120.0K
YoY Change 20.0% 0.0% -40.0%
Cash From Operating Activities -$11.69M -$9.720M -$8.650M
YoY Change 53.01% 12.37% -52.58%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $17.00K $2.000K
YoY Change -100.0% 750.0% -98.25%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$20.00K $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$94.07M $132.0K
YoY Change -71368.18% -46.34%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 560.0K 96.62M 840.0K
YoY Change 60.0% 11402.38% 18.98%
NET CHANGE
Cash From Operating Activities -11.69M -9.720M -8.650M
Cash From Investing Activities 0.000 -20.00K 0.000
Cash From Financing Activities 560.0K 96.62M 840.0K
Net Change In Cash -11.13M 86.88M -7.810M
YoY Change 50.61% -1212.42% -55.75%
FREE CASH FLOW
Cash From Operating Activities -$11.69M -$9.720M -$8.650M
Capital Expenditures $0.00 $17.00K $2.000K
Free Cash Flow -$11.69M -$9.737M -$8.652M
YoY Change 51.03% 12.54% -52.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
128232537 shares
CY2014Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
224000
CY2014Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
1000000
CY2014Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
792000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60385000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128232537 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128232537 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.08
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5878611 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.09
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3185297 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.08
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4572935 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5924297 shares
CY2015Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
405000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10492000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
128000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
779000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-450843000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
571318000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8220000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
120603000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131648000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1088000
CY2015Q1 us-gaap Liabilities
Liabilities
11045000
CY2015Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
958000
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
553000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129684000
CY2015Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7700000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
426000
CY2015Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
62000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39564000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
857000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
39259000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21297000
CY2015Q1 us-gaap Assets
Assets
131648000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
491000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
130603000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68204000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104452105 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104452105 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3781162 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.10
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6505663 shares
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
280000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10826000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
104000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2004000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-372612000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
406349000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7182000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
33841000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45237000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1360000
CY2014Q4 us-gaap Liabilities
Liabilities
11396000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
570000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42803000
CY2014Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
531000
CY2014Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
145000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1139000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4130000
CY2014Q4 us-gaap Assets
Assets
45237000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
491000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
44087000
CY2015Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
In connection with such transfer, the terms of the License also require the Company and Intrexon to enter into a research and development agreement with MD Anderson pursuant to which the Company will provide funding for certain research and development activities of MD Anderson for a period of three years
CY2009 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9446 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
80500 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.34
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8654000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100229200 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0176 pure
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9455 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0211 pure
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16996001 shares
CY2014Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
82000
CY2014Q1 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2014Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-11000
CY2014Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-118000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-359000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9784000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2014Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
132000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-9711000
CY2014Q1 us-gaap Interest Paid
InterestPaid
0
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-200000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6542000
CY2014Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-47000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7819000
CY2014Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
167000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
124000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
837000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-605000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2000
CY2014Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9984000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
969000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3442000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
156000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1223000
CY2014Q1 ziop Revenue Recognition Period
RevenueRecognitionPeriod
P75M
CY2014Q1 ziop Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8548 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
50000 shares
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y3M29D
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.29
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
CY2015Q1 dei Trading Symbol
TradingSymbol
ZIOP
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.58
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9717000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
39166 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
113410250 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0163 pure
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M10D
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.26
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M29D
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.10
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-78231000
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8681 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0164 pure
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6020370 shares
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
592200 shares
CY2015Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
94320000
CY2015Q1 us-gaap Contracts Revenue
ContractsRevenue
272000
CY2015Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-83000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-282000
CY2015Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2541000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-78227000
CY2015Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2015Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
246000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
CY2015Q1 us-gaap Interest Paid
InterestPaid
0
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1093000
CY2015Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
67285000
CY2015Q1 us-gaap Stock Issued1
StockIssued1
67285000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-272000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74249000
CY2015Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
108000
CY2015Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
246000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
86881000
CY2015Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
177000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
122000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
96615000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94320000
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
267000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1037000
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
67285000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17000
CY2015Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
78499000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2541000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4250000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1224000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1093000

Files In Submission

Name View Source Status
0001193125-15-177165-index-headers.html Edgar Link pending
0001193125-15-177165-index.html Edgar Link pending
0001193125-15-177165.txt Edgar Link pending
0001193125-15-177165-xbrl.zip Edgar Link pending
d914910d10q.htm Edgar Link pending
d914910dex311.htm Edgar Link pending
d914910dex312.htm Edgar Link pending
d914910dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g914910g45u60.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20150331.xml Edgar Link completed
ziop-20150331.xsd Edgar Link pending
ziop-20150331_cal.xml Edgar Link unprocessable
ziop-20150331_def.xml Edgar Link unprocessable
ziop-20150331_lab.xml Edgar Link unprocessable
ziop-20150331_pre.xml Edgar Link unprocessable